C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma

Taizo Uchimoto(Osaka University of Pharmaceutical Sciences), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Takuya Tsujino(Osaka University of Pharmaceutical Sciences), Atsuhiko Yoshizawa(Fujita Health University Hospital), Mamoru Hashimoto(University of Pittsburgh), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Wataru Fukuokaya(Jikei University School of Medicine), Jun Miki(Jikei University School of Medicine), Keiichiro Mori(Jikei University School of Medicine), Kazuki Nishimura(Osaka University of Pharmaceutical Sciences), Kyosuke Nishio(Osaka University of Pharmaceutical Sciences), Takafumi Yanagisawa(Jikei University School of Medicine), Takahiro Adachi(Tokyo Medical University), Shunsuke Tsuduki(Jikei University School of Medicine), Kiyoshi Takahara(Osaka Medical and Pharmaceutical University), Shutaro Yamamoto, Hirotsugu Uemura(Kindai University), Takuya Higashio(Osaka University of Pharmaceutical Sciences), Masanobu Saruta(Fujita Health University), Yoshio Ohno(Tokyo Medical University), Teruo Inamoto(Hamamatsu University), Takeshi Hashimoto(Tokyo Medical University), Kazumasa Komura(Kawasaki Medical School), Kazutoshi Fujita(Kindai University), Ryoichi Shiroki(Fujita Health University), Takahiro Kimura(Jikei University School of Medicine), Takuya Matsuda(Nagoya University), Shuya Tsuchida(Osaka University of Pharmaceutical Sciences), Tatsuo Fukushima(Osaka University of Pharmaceutical Sciences), Ko Nakamura, Yosuke Hirasawa(Cedars-Sinai Medical Center)
Targeted Oncology
May 28, 2024
Cited by 12


Related Papers